Net Profit Margin
since 2013
Paying user area
Try for free
IQVIA Holdings Inc. pages available for free this week:
- Analysis of Long-term (Investment) Activity Ratios
- Analysis of Reportable Segments
- Enterprise Value (EV)
- Price to FCFE (P/FCFE)
- Capital Asset Pricing Model (CAPM)
- Operating Profit Margin since 2013
- Current Ratio since 2013
- Total Asset Turnover since 2013
- Price to Book Value (P/BV) since 2013
- Price to Sales (P/S) since 2013
The data is hidden behind: . Unhide it.
Get full access to the entire website from $10.42/mo, or
get 1-month access to IQVIA Holdings Inc. for $22.49.
This is a one-time payment. There is no automatic renewal.
We accept:
Calculation
IQVIA Holdings Inc., net profit margin, long-term trends, calculation
| Net profit margin | = | 100 | × | Net income attributable to IQVIA Holdings Inc.1 | ÷ | Revenues1 | |
|---|---|---|---|---|---|---|---|
| Dec 31, 2022 | = | 100 | × | ÷ | |||
| Dec 31, 2021 | = | 100 | × | ÷ | |||
| Dec 31, 2020 | = | 100 | × | ÷ | |||
| Dec 31, 2019 | = | 100 | × | ÷ | |||
| Dec 31, 2018 | = | 100 | × | ÷ | |||
| Dec 31, 2017 | = | 100 | × | ÷ | |||
| Dec 31, 2016 | = | 100 | × | ÷ | |||
| Dec 31, 2015 | = | 100 | × | ÷ | |||
| Dec 31, 2014 | = | 100 | × | ÷ | |||
| Dec 31, 2013 | = | 100 | × | ÷ |
Based on: 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31), 10-K (reporting date: 2014-12-31), 10-K (reporting date: 2013-12-31).
1 US$ in millions
- Revenues
- The revenues showed a general upward trend throughout the period from 2013 to 2022. Starting at $5,100 million in 2013, revenues increased consistently almost every year, reaching $14,410 million by 2022. The most notable increases occurred between 2016 and 2017, and again between 2020 and 2021, indicating periods of strong growth momentum.
- Net Income Attributable to IQVIA Holdings Inc.
- Net income exhibited considerable volatility over the years. Initial growth was observed from 2013 ($227 million) to 2015 ($387 million), followed by a sharp decline in 2016 to $115 million. In 2017, there was a significant surge to $1,309 million, the highest value in the period. However, the subsequent years saw fluctuations with a notable dip in 2018 and 2019, before recovering modestly in 2020 and then increasing again to $1,091 million in 2022. These fluctuations suggest episodes of extraordinary gains or losses impacting net profitability.
- Net Profit Margin
- The net profit margin varied substantially across the years, reflecting inconsistent profit efficiency relative to revenues. Starting at 4.44% in 2013, the margin improved to a peak of 6.75% by 2015. There was a sharp decrease in 2016 to 1.67%, followed by a remarkable rise to 13.44% in 2017, the highest margin observed. Subsequent years demonstrated a decline again with margins below 3% in 2018 through 2020. The margin improved notably in 2021 and 2022, reaching 7.57% by the end of the period, suggesting enhanced profitability in recent years.
- Overall Insights
- While revenues have steadily increased over the evaluated period, indicating consistent business expansion, net income and profit margins show considerable volatility. The spikes and drops in net income and profit margin suggest the influence of non-recurring items or operational challenges in some years. The recent trends in 2021 and 2022 demonstrate an improvement in profitability metrics, aligning with the continued revenue growth. The company appears to be managing profitability more effectively in the latter years despite earlier variability.
Comparison to Competitors
IQVIA Holdings Inc., net profit margin, long-term trends, comparison to competitors
| IQVIA Holdings Inc. | AbbVie Inc. | Amgen Inc. | Bristol-Myers Squibb Co. | Danaher Corp. | Eli Lilly & Co. | Gilead Sciences Inc. | Johnson & Johnson | Merck & Co. Inc. | Pfizer Inc. | Regeneron Pharmaceuticals Inc. | Thermo Fisher Scientific Inc. | Vertex Pharmaceuticals Inc. | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Dec 31, 2022 | |||||||||||||
| Dec 31, 2021 | |||||||||||||
| Dec 31, 2020 | |||||||||||||
| Dec 31, 2019 | |||||||||||||
| Dec 31, 2018 | |||||||||||||
| Dec 31, 2017 | |||||||||||||
| Dec 31, 2016 | |||||||||||||
| Dec 31, 2015 | |||||||||||||
| Dec 31, 2014 | |||||||||||||
| Dec 31, 2013 |
Based on: 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31), 10-K (reporting date: 2014-12-31), 10-K (reporting date: 2013-12-31).
Comparison to Sector (Pharmaceuticals, Biotechnology & Life Sciences)
IQVIA Holdings Inc., net profit margin, long-term trends, comparison to sector (pharmaceuticals, biotechnology & life sciences)
| IQVIA Holdings Inc. | Pharmaceuticals, Biotechnology & Life Sciences | |
|---|---|---|
| Dec 31, 2022 | ||
| Dec 31, 2021 | ||
| Dec 31, 2020 | ||
| Dec 31, 2019 | ||
| Dec 31, 2018 | ||
| Dec 31, 2017 | ||
| Dec 31, 2016 | ||
| Dec 31, 2015 | ||
| Dec 31, 2014 | ||
| Dec 31, 2013 |
Based on: 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31), 10-K (reporting date: 2014-12-31), 10-K (reporting date: 2013-12-31).
Comparison to Industry (Health Care)
IQVIA Holdings Inc., net profit margin, long-term trends, comparison to industry (health care)
| IQVIA Holdings Inc. | Health Care | |
|---|---|---|
| Dec 31, 2022 | ||
| Dec 31, 2021 | ||
| Dec 31, 2020 | ||
| Dec 31, 2019 | ||
| Dec 31, 2018 | ||
| Dec 31, 2017 | ||
| Dec 31, 2016 | ||
| Dec 31, 2015 | ||
| Dec 31, 2014 | ||
| Dec 31, 2013 |
Based on: 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31), 10-K (reporting date: 2014-12-31), 10-K (reporting date: 2013-12-31).